Veracyte (NASDAQ:VCYT – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Veracyte and CAMP4 Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veracyte | 1 | 2 | 6 | 2 | 2.82 |
| CAMP4 Therapeutics | 1 | 1 | 7 | 0 | 2.67 |
Veracyte presently has a consensus price target of $54.33, indicating a potential upside of 28.42%. CAMP4 Therapeutics has a consensus price target of $9.56, indicating a potential upside of 113.45%. Given CAMP4 Therapeutics’ higher probable upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Veracyte.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veracyte | $517.15 million | 6.58 | $66.35 million | $1.41 | 30.01 |
| CAMP4 Therapeutics | $3.50 million | 80.32 | -$80.40 million | ($2.32) | -1.93 |
Veracyte has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Veracyte and CAMP4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veracyte | 20.37% | 9.26% | 8.61% |
| CAMP4 Therapeutics | -2,543.74% | -252.79% | -85.65% |
Volatility & Risk
Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Summary
Veracyte beats CAMP4 Therapeutics on 10 of the 13 factors compared between the two stocks.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
